Program
GP MDI
Also written as “GP MDI 28.8 μg”, “GP MDI 14.4 μg” and “GP MDI 7.2 μg”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive, led by AstraZeneca.
Furthest: phase 3, since May 13, 20133 company-led studies, 1 open or runningNext primary completion: May 23, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 31 open or running | phase 3since May 13, 2013 | May 13, 2013 | May 23, 2029phase 2 · NCT07525375 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 13, 2013First study: phase 3 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT01854645 · 2,103 enrolled · United States, Australia, New Zealand
- Nov 20, 2017Phase 3 study in AsthmaNCT03358147 · 1,077 enrolled · United States
- Apr 7, 2026Phase 2 study in AsthmaNCT07525375 · 69 planned · United States, Argentina, Czechia and more
Ahead
- May 23, 2029Primary completion: phase 2 study in AsthmaNCT07525375
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07525375Asthma · United States, Argentina, Czechia and more | 2 | Recruiting | May 23, 2029 | 69 |
| NCT03358147Asthma · United States | 3 | Completed | Sep 12, 2019 | 1,077 |
| NCT01854645Pulmonary Disease, Chronic Obstructive · United States, Australia, New Zealand | 3 | Completed | Feb 2015 | 2,103 |
How it is read
Names in the registry
- “GP MDI”, 2 entries
- “GP MDI 28.8 μg”, 1 entry
- “GP MDI 14.4 μg”, 1 entry
- “GP MDI 7.2 μg”, 1 entry
Conditions, from the studies’ own filings
- Asthma, 2 studies
- Pulmonary Disease, Chronic Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.